摘要
目的探讨甘草酸对胶质瘤患者血清中血小板源性生长因子(platelet derived growth factor,PDGF)、白细胞介素-17(interleukin 17,IL-17)、单核细胞趋化蛋白1(monocyte chemotactic protein 1,MCP-1)及血清应答因子(serum response factor,SRF)的影响。方法收集湖北省浠水县人民医院收治的脑胶质瘤患者48例,随机分为对照组和实验组,每组24例,所有患者进行手术治疗,术后对照组给予替莫唑胺胶囊(150 mg/m2)治疗,1次/天,口服,28d为1个治疗周期内连续服用5天;实验组在对照组基础上给予复方甘草酸单铵注射液40 m L,溶于250 m L 5%葡萄糖溶液中静点,1次/天,4周为1个疗程。2组患者均治疗2个疗程后,对所有患者的血清PDGF、IL-17、MCP-1及SRF进行检测。结果治疗后,与对照组比较,实验组患者的血清PDGF水平较低(P<0.05);实验组患者的血清IL-17水平较低(P<0.05);实验组患者的血清MCP-1水平较高(P<0.05);实验组患者的血清SRF水平较低(P<0.05)。结论甘草酸能够明显降低胶质瘤患者血清PDGF、IL-17及血清SRF,升高MCP-1水平,对临床有指导意义。
Objective To analyse effect of glycyrrhizin on serum levels of platelet derived growth factor( PDGF),interleukin 17( IL-17),monocyte chemotactic protein 1( MCP-1) and serum response factor( SRF) in patients with glioma. Methods 48 patients who were diagnosed with glioma in our hospital were collected. All patients were randomly divided into experimental group and control group,24 cases in each group. All patients were treated with surgery,control group was treated with temozolomid capsule( 150 mg / m2) orally,one times per day,28 days for a treatment period of5 days continuous administration. On the basis of control group,experimental group was treated with compound ammonium glycyrrhetate injection 40 m L,dissolved in 250 m L 5% glucose solution intravenously,one times per day,four weeks was a period of treatment. After two groups were treated two period of treatment,the serum levels of PDGF,IL-17,MCP-1and SRF were detected in all patients. Results After treatment,compared with control group,the serum PDGF level was lower than that of experimental group( P〈0. 05); the serum IL-17 level was lower than that of experimental group( P〈0. 05);the serum MCP-1 level was higher than that of experimental group( P〈0. 05); the serum SRF level was lower than that of experimental group( P〈0. 05). Conclusion Glycyrrhizin could significantly reduce the serum PDGF,IL-17 and SRF levels,increase MCP-1 levels,have guidance significance for clinic.
出处
《中国生化药物杂志》
CAS
2015年第9期94-96,共3页
Chinese Journal of Biochemical Pharmaceutics